BIOON/ --Novan公司从美国Biomedical Advanced Research and Development Authority (BARDA)获得资助用以开发一项用一氧化氮气体治疗烫伤的技术。这项技术是基于1998年获得诺贝尔奖的一项研究成果，一氧化氮气体能够对烫伤处微生物生长等起抑制作用，同时还能防止炎症发生和促进组织再生。BARDA同意对这个项目提供长达两年的资助，该技术也将可能成为第一个FDA批准的专门用于处理烫伤的疗法。

详细英文报道：

Novan Therapeutics landed $7.8 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to further develop the North Carolina-based company's technology that delivers nitric oxide gas to thermal wounds.

Novan's delivery technology for the release of nitric oxide is critical to its success as a therapeutic. Because the active ingredient is a gas, it must be stored in a molecule that carefully controls the timing of the release, as well as the amount that is used.

The technology is based on the 1998 Nobel Prize-winning discovery of nitric oxide's ability to perform several therapeutic tasks, including, according to the company, preventing clotting, regulating inflammation, revitalizing tissue, killing invading microorganisms and neutralizing cancer cells.

BARDA has agreed to a two-year contract for the development, which would be the first FDA-approved drug with an indication for burn healing, according to an in-Pharma Technologist report.

Novan designed its burn medication for "a mass casualty event caused by natural or intentional threats to public health (that) could result in tens of thousands of burn patients, which would overwhelm the burn care infrastructure presently available in the United States," according to the company.

Novan has only one product in clinical trials, which is a nitric oxide therapy for acne. The company started in 2008.